Donald Trump Usa Britain city Sanofi covid-19 death patient Donald Trump Usa Britain city Sanofi

Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials amid safety concerns

Reading now: 849
www.livemint.com

The moves come after the WHO paused its hydroxychloroquine trial after The Lancet reported patients getting the drug had increased death rates and irregular heartbeats PARIS : Sanofi has temporarily stopped recruiting new COVID-19 patients for its two clinical trials on hydroxychloroquine and will not supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up, it said on Friday.

The moves come after the World Health Organization paused its large trial of hydroxychloroquine after the British journal The Lancet reported patients getting the drug had increased death rates and irregular heartbeats.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA